Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:LEGN NASDAQ:SDGR NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$186.45+0.0%$164.27$122.80▼$207.84$5.40B0.64289,505 shs171,605 shsLEGNLegend Biotech$31.67-1.4%$33.80$27.34▼$47.79$5.93B0.231.43 million shs1.12 million shsSDGRSchrodinger$21.96+5.6%$19.78$16.60▼$28.47$1.53B1.741.23 million shs1.35 million shsTGTXTG Therapeutics$33.49-3.2%$32.77$22.61▼$46.48$5.49B1.971.52 million shs1.97 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech-2.29%-3.40%+12.69%+24.28%+6.40%LEGNLegend Biotech-2.28%-4.77%-5.78%-27.37%-28.70%SDGRSchrodinger-0.38%+0.87%+5.43%-7.56%+11.30%TGTXTG Therapeutics-1.79%-1.31%-1.09%-5.31%+42.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$186.45+0.0%$164.27$122.80▼$207.84$5.40B0.64289,505 shs171,605 shsLEGNLegend Biotech$31.67-1.4%$33.80$27.34▼$47.79$5.93B0.231.43 million shs1.12 million shsSDGRSchrodinger$21.96+5.6%$19.78$16.60▼$28.47$1.53B1.741.23 million shs1.35 million shsTGTXTG Therapeutics$33.49-3.2%$32.77$22.61▼$46.48$5.49B1.971.52 million shs1.97 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech-2.29%-3.40%+12.69%+24.28%+6.40%LEGNLegend Biotech-2.28%-4.77%-5.78%-27.37%-28.70%SDGRSchrodinger-0.38%+0.87%+5.43%-7.56%+11.30%TGTXTG Therapeutics-1.79%-1.31%-1.09%-5.31%+42.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.75Moderate Buy$223.0019.60% UpsideLEGNLegend Biotech 2.73Moderate Buy$66.56110.15% UpsideSDGRSchrodinger 2.38Hold$26.2919.70% UpsideTGTXTG Therapeutics 2.67Moderate Buy$49.0046.31% UpsideCurrent Analyst Ratings BreakdownLatest SDGR, LEGN, KRYS, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$224.0010/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.0010/17/2025KRYSKrystal BiotechBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$182.00 ➝ $255.0010/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.0010/14/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/9/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$78.00 ➝ $76.0010/8/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $28.0010/8/2025TGTXTG TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/7/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M18.57$4.53 per share41.14$32.90 per share5.67LEGNLegend Biotech$627.24M9.32N/AN/A$5.70 per share5.56SDGRSchrodinger$207.54M7.79N/AN/A$5.78 per share3.80TGTXTG Therapeutics$329M16.15$0.11 per share293.59$1.43 per share23.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.9237.9018.50N/A40.85%15.21%13.81%11/3/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/5/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3790.5133.49N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest SDGR, LEGN, KRYS, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LEGNLegend Biotech-$0.08N/AN/AN/A$277.91 millionN/A11/5/2025Q3 2025SDGRSchrodinger-$0.72N/AN/AN/A$50.51 millionN/A11/3/2025Q3 2025KRYSKrystal Biotech$1.04N/AN/AN/A$93.72 millionN/A11/3/2025Q3 2025TGTXTG Therapeutics$0.24N/AN/AN/A$152.12 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.689.33LEGNLegend Biotech0.304.714.57SDGRSchrodingerN/A3.303.30TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%LEGNLegend Biotech70.89%SDGRSchrodinger79.05%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%LEGNLegend Biotech0.02%SDGRSchrodinger21.00%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableSDGR, LEGN, KRYS, and TGTX HeadlinesRecent News About These CompaniesDrug launch prices rise significantly outpacing inflation and GDP growth: ICEROctober 23 at 12:59 PM | msn.comVIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.79 Million in TG Therapeutics, Inc. $TGTXOctober 23 at 4:55 AM | marketbeat.comEnvestnet Portfolio Solutions Inc. Takes $543,000 Position in TG Therapeutics, Inc. $TGTXOctober 22 at 3:36 AM | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from AnalystsOctober 12, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Given Hold (C-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comAnalysts Offer Predictions for TG Therapeutics Q3 EarningsOctober 8, 2025 | marketbeat.comHC Wainwright Weighs in on TG Therapeutics FY2029 EarningsOctober 7, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Raised to "Strong-Buy" at HC WainwrightOctober 7, 2025 | marketbeat.comTG Therapeutics assumed with a Buy at H.C. WainwrightOctober 6, 2025 | msn.comWhat TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For ShareholdersOctober 4, 2025 | uk.finance.yahoo.comInstitutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gainOctober 4, 2025 | finance.yahoo.comTG announces updated data presentations from ULTIMATE I, II Phase 3 trialsSeptember 25, 2025 | msn.comTG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous ...September 24, 2025 | finanznachrichten.deTG Therapeutics Reports Six-Year Data for BRIUMVI® Showing Exceptional Efficacy and Consistent Safety Profile in Multiple Sclerosis TreatmentSeptember 24, 2025 | quiverquant.comQNew Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI TreatmentSeptember 24, 2025 | globenewswire.comTG Therapeutics price target raised to $55 from $53 at B. RileySeptember 17, 2025 | msn.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13, 2025 | insidertrades.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10, 2025 | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDGR, LEGN, KRYS, and TGTX Company DescriptionsKrystal Biotech NASDAQ:KRYS$186.45 +0.03 (+0.02%) Closing price 04:00 PM EasternExtended Trading$186.38 -0.07 (-0.04%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Legend Biotech NASDAQ:LEGN$31.67 -0.44 (-1.37%) Closing price 04:00 PM EasternExtended Trading$31.70 +0.03 (+0.09%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Schrodinger NASDAQ:SDGR$21.96 +1.17 (+5.63%) Closing price 04:00 PM EasternExtended Trading$21.90 -0.06 (-0.28%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.TG Therapeutics NASDAQ:TGTX$33.49 -1.10 (-3.18%) Closing price 04:00 PM EasternExtended Trading$33.44 -0.05 (-0.13%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
